Cirata (CRTA) investor relations material

Executive summary

• Revenue for H1 FY26 was $1.0m, down from $4.8m in H1 FY25, reflecting lower bookings and deferred revenue movement.

• Adjusted EBITDA loss increased to $5.3m from $4.6m YoY, driven by lower revenue partially offset by reduced operating expenses.

• Achieved first-ever positive cash flow quarter in Q1 FY26, but overall H1 saw a net cash outflow of $1.4m.

• Pipeline value and quality improved significantly, with new sales team fully staffed by June 2026.

• Completed an oversubscribed fundraise post-period, raising $7.2m gross to support growth and balance sheet stability.

Financial highlights

• Total bookings were $0.5m (H1 FY25: $3.8m); closing ACV rose to $5.3m from $4.8m at year-end 2025.

• Billings for H1 FY26 were $2.8m; RCB at period end was $5.7m, with $3.3m expected to be billed within 12 months.

• Cash at 30 June 2026 was $2.6m, down from $6.1m YoY; cash overheads for H1 were $6.3m, in line with annualized guidance.

• Total comprehensive loss for the period was $4.8m (H1 FY25: $4.6m loss).

• Deferred revenue at period end was $0.1m, down from $2.0m YoY.

Outlook and guidance

• FY26 annualized cost base expected to remain at $12-13m, maintaining cost discipline.

• Cash flow breakeven achieved in Q1, but full-year breakeven may be delayed due to longer sales cycles and timing of key contract closures.

• Pipeline continues to grow, especially in the USA, UK, and ANZ, but full sales productivity ramp expected to take several months.

• Proceeds from the July 2026 fundraise will support new customer acquisition and product scaling.